MENLO
PARK, Calif., Aug. 21,
2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a
healthcare company whose mission is to detect cancer early when it
can be cured, today announced that company management will present
at the Morgan Stanley 22nd Annual Global Healthcare Conference at
3:20 p.m. ET on Sept. 4, 2024.
Live and replay webcasts may be accessed in the investor
relations section of GRAIL's website at investors.grail.com. The
webcast will be archived and available for reply for at least 30
days after the event.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer
early, when it can be cured. GRAIL is focused on alleviating the
global burden of cancer by using the power of next-generation
sequencing, population-scale clinical studies, and state-of-the-art
machine learning, software, and automation to detect and identify
multiple deadly cancer types in earlier stages. GRAIL's targeted
methylation-based platform can support the continuum of care for
screening and precision oncology, including multi-cancer early
detection in symptomatic patients, risk stratification, minimal
residual disease detection, biomarker subtyping, treatment and
recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
For more information, visit grail.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-the-morgan-stanley-22nd-annual-global-healthcare-conference-302227805.html
SOURCE GRAIL, Inc.